Edwards Lifesciences Corporation (EW) is a Medical - Devices company in the Healthcare sector, currently trading at $78.20. It has a SharesGrow Score of 74/100, indicating a above average investment profile with 6 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of EW = $108.39 (+38.6% from the current price, the stock appears undervalued). Analyst consensus target is EW = $96 (+23.2% upside).
Valuation: EW trades at a trailing Price-to-Earnings (P/E) of 43.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 3.68.
Financials: revenue is $6.1B, +4.6%/yr average growth. Net income is $1.1B, growing at +38.5%/yr. Net profit margin is 17.7% (healthy). Gross margin is 78.1% (-1.8 pp trend).
Balance sheet: total debt is $705M against $10.3B equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 3.72 (strong liquidity). Debt-to-assets is 5.1%. Total assets: $13.7B.
Analyst outlook: 32 / 48 analysts rate EW as buy (67%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 32/100 (Fail), Growth 73/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 76/100 (Pass), Future 67/100 (Pass), Income 70/100 (Pass).
